Bluebird Bio Withdraws Zynteglo From Germany Over Pricing

Germany Is The Only Country Where the Gene Therapy Was Marketed

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.

Bluebird bio
pricing concerns promt bluebird to pull Zynteglo from Germany • Source: Alamy

Price negotiations for bluebird bio’s gene therapy Zynteglo in Germany have failed and the company is withdrawing the high-cost product from the market. Not only is Germany the first country where the one-time gene therapy for treating transfusion-dependent beta-thalassaemia (TDT) was launched, it is also currently the only EU country where the treatment had been given to patients outside of a clinical trial setting.

Zynteglo has not been approved in any other markets worldwide. It is bluebird’s first product and will serve as a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     
    • By Anabel Costa-Ferreira and Ian Schofield

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography